



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2023





© 2023 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
687 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.bccfe.ca](http://www.bccfe.ca)  
Email: [info@bccfe.ca](mailto:info@bccfe.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

February 2023

N = 7534



Health Authority	Male	Female	All
FRASER	1510	468	1978
INTERIOR	444	122	566
NORTHERN	153	76	229
VANCOUVER COASTAL	3285	443	3728
VANCOUVER ISLAND	823	169	992
	<b>6215</b>	<b>1278</b>	<b>7493</b>
		<b>Unknown/not stated:</b>	<b>41</b>
		<b>Total:</b>	<b>7534</b>

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (February 2018 - February 2023)




**Notes:**

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (February 2018 - February 2023)




**Notes:**

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






### 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (February 2018 - February 2023)






### 1.5 BC-CfE Enrolment: New Antiretroviral Participants (February 2018 - February 2023)






1.6 Percent Distribution of Active Participants by CD4 Count  
(February 2018 - February 2023)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(February 2018 - February 2023)






### 1.8 Active and Inactive Participants (February 2018 - February 2023)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (February 2018 - February 2023)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (February 2018 - February 2023)






### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(February 2018 - February 2023)






### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (February 2018 - February 2023)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(February 2018 - February 2023)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (February 2018 - February 2023)






**1.15 Distribution of Participants on Non-Nucleosides  
at the time of first start of ARV Therapy by INGREDIENT**  
(February 2018 - February 2023)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (February 2018 - February 2023)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(February 2018 - February 2023)






1.18 Baseline CD4 for Antiretroviral First Starts  
(February 2018 - February 2023)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (February 2018 - February 2023)






### 1.20 Cumulative Resistance Testing Results by Resistance Category (February 2018 - February 2023)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (February 2018 - February 2023)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	31	4	0	4	1	1030	3	<40	4
1988	32	5	0	5	2	315	5	<40	3
1989	30	50	1	51	22	530	49	<40	3
1990	28	52	1	53	29	550	49	<40	3
1991	29	36	3	39	12	535	35	<40	3
1992	28	52	5	57	21	610	56	<40	3
1993	27	115	14	129	71	540	121	<40	3
1994	26	67	13	80	48	480	75	<40	3
1995	26	121	18	139	71	600	131	<40	3
1996	24	301	48	349	184	555	312	<40	3
1997	22	257	32	289	161	570	260	<40	3
1998	21	179	41	220	138	565	200	<40	3
1999	21	150	39	189	115	560	172	<40	3
2000	21	113	29	142	84	600	132	<40	3
2001	21	108	25	133	79	530	124	<40	3
2002	20	114	25	139	76	595	123	<40	3
2003	19	132	24	156	90	567	141	<40	3
2004	18	141	35	176	110	580	163	<40	3
2005	17	174	40	214	126	650	189	<40	3
2006	16	163	40	203	122	590	182	<40	3
2007	15	228	43	271	160	650	247	<40	3
2008	14	264	60	324	223	620	293	<40	3
2009	13	289	61	350	214	650	316	<40	3
2010	12	252	66	318	193	680	290	<40	3
2011	11	314	71	385	244	665	346	<40	3
2012	10	252	60	312	189	720	281	<40	3
2013	9	249	66	315	201	670	288	<40	3
2014	9	264	50	314	181	720	275	<40	3
2015	8	261	44	305	186	680	274	<40	3
2016	7	239	52	291	166	700	256	<40	3
2017	6	199	30	229	150	680	207	<40	3
2018	5	183	50	233	139	710	204	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	4	220	41	261	176	665	232	<40	3
2020	3	182	53	235	165	740	209	<40	3
2021	2	193	35	228	134	600	200	<40	3
2022	1	267	54	321	233	620	298	<40	3
2023	0	49	12	61	46	545	55	<40	3
<b>Total:</b>		<b>6239</b>	<b>1281</b>	<b>7520</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1151	620
MAY-2022	7477	763	1998	<40	1304	620
JUN-2022	7482	759	1839	<40	1200	630
JUL-2022	7495	754	1761	<40	1139	645
AUG-2022	7493	758	1990	<40	1225	620
SEP-2022	7443	771	1787	<40	1087	640
OCT-2022	7469	777	1849	<40	1161	640
NOV-2022	7502	783	1898	<40	1188	630
DEC-2022	7547	787	1607	<40	997	640
JAN-2023	7588	793	2052	<40	1294	650
FEB-2023	7534	807	1728	<40	979	630

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	775	334	60	<40	43	490
JUN-2022	778	317	61	<40	43	400
JUL-2022	781	297	61	<50	35	453
AUG-2022	803	275	59	78	48	550
SEP-2022	860	223	71	<40	53	460
OCT-2022	843	230	83	<40	61	500
NOV-2022	830	236	80	50	59	490
DEC-2022	792	267	57	<40	45	560
JAN-2023	750	322	62	<40	44	553
FEB-2023	800	253	66	<40	51	550

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14504
FEB-2022	7371	856	8	9	151	211	-61	14529
MAR-2022	7432	800	16	9	232	160	61	14558
APR-2022	7397	834	11	1	156	178	-35	14578
MAY-2022	7450	775	13	13	205	146	53	14602
JUN-2022	7457	778	11	15	178	170	7	14639
JUL-2022	7469	781	10	13	188	176	12	14678
AUG-2022	7469	803	15	17	169	171	0	14716
SEP-2022	7424	860	13	15	146	191	-45	14744
OCT-2022	7446	843	14	16	196	171	22	14779
NOV-2022	7483	830	9	17	209	177	37	14818
DEC-2022	7518	792	19	8	215	166	35	14845
JAN-2023	7560	750	20	10	194	142	42	14880
FEB-2023	7520	800	10	14	158	202	-40	14906

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	<b>7465</b>	6.68%	86.64%	6.10%	0.58%	<b>100.00%</b>
FEB-2022	525	6371	445	45	<b>7386</b>	7.11%	86.26%	6.02%	0.61%	<b>100.00%</b>
MAR-2022	550	6408	455	45	<b>7458</b>	7.37%	85.92%	6.10%	0.60%	<b>100.00%</b>
APR-2022	567	6357	450	46	<b>7420</b>	7.64%	85.67%	6.06%	0.62%	<b>100.00%</b>
MAY-2022	597	6381	452	47	<b>7477</b>	7.98%	85.34%	6.05%	0.63%	<b>100.00%</b>
JUN-2022	614	6376	450	42	<b>7482</b>	8.21%	85.22%	6.01%	0.56%	<b>100.00%</b>
JUL-2022	634	6371	445	45	<b>7495</b>	8.46%	85.00%	5.94%	0.60%	<b>100.00%</b>
AUG-2022	643	6366	441	43	<b>7493</b>	8.58%	84.96%	5.89%	0.57%	<b>100.00%</b>
SEP-2022	663	6296	439	45	<b>7443</b>	8.91%	84.59%	5.90%	0.60%	<b>100.00%</b>
OCT-2022	679	6310	439	41	<b>7469</b>	9.09%	84.48%	5.88%	0.55%	<b>100.00%</b>
NOV-2022	696	6318	446	42	<b>7502</b>	9.28%	84.22%	5.95%	0.56%	<b>100.00%</b>
DEC-2022	709	6347	449	42	<b>7547</b>	9.39%	84.10%	5.95%	0.56%	<b>100.00%</b>
JAN-2023	721	6378	445	44	<b>7588</b>	9.50%	84.05%	5.86%	0.58%	<b>100.00%</b>
FEB-2023	735	6331	429	39	<b>7534</b>	9.76%	84.03%	5.69%	0.52%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3229 44%	9 23%	1218 17%	35 90%	4343 59%
AUG-2022	5 14%	2992 41%	4 11%	2262 31%	0 0%	18 0%	29 78%	3271 45%	3 8%	1178 16%	32 86%	4353 59%
SEP-2022	4 14%	2953 40%	3 11%	2196 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1173 16%	24 86%	4352 60%
OCT-2022	6 17%	2951 40%	4 11%	2174 30%	0 0%	16 0%	29 83%	3350 46%	0 0%	1143 16%	29 83%	4388 60%
NOV-2022	7 18%	2948 40%	5 13%	2158 29%	0 0%	15 0%	26 68%	3387 46%	6 16%	1136 15%	31 82%	4417 60%
DEC-2022	4 15%	2952 40%	3 11%	2149 29%	1 4%	16 0%	18 67%	3447 47%	5 19%	1110 15%	23 85%	4447 60%
JAN-2023	6 17%	2973 40%	1 3%	2149 29%	1 3%	16 0%	23 66%	3493 47%	8 23%	1098 15%	29 83%	4470 60%
FEB-2023	3 12%	2949 40%	1 4%	2101 28%	0 0%	17 0%	20 77%	3508 47%	3 12%	1069 14%	23 88%	4454 60%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	386 26%	1 100%	1028 70%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	368 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	355 25%	0 0%	1002 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	995 72%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	341 24%	1 100%	1008 72%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
JAN-2023	0 0%	0 0%	0 0%	339 25%	1 100%	995 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	0 0%	0 0%	321 24%	0 0%	956 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	271 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	183 18%	2 67%	261 26%	0 0%	108 11%	0 0%	269 26%	0 0%	197 19%
DEC-2022	0 0%	186 19%	1 25%	254 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	203 21%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	11 73%	2421 43%	2 13%	2468 44%	1 7%	347 6%	0 0%	0 0%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2443 44%	6 29%	2437 44%	0 0%	331 6%	0 0%	0 0%	0 0%	21 0%	0 0%	369 7%
MAR-2022	23 85%	2536 45%	3 11%	2460 43%	1 4%	324 6%	0 0%	0 0%	0 0%	21 0%	0 0%	370 7%
APR-2022	14 74%	2574 45%	5 26%	2436 43%	0 0%	312 5%	0 0%	0 0%	0 0%	20 0%	0 0%	366 6%
MAY-2022	17 77%	2666 46%	5 23%	2455 43%	0 0%	309 5%	0 0%	0 0%	0 0%	22 0%	0 0%	360 6%
JUN-2022	29 85%	2710 47%	5 15%	2454 42%	0 0%	300 5%	0 0%	0 0%	0 0%	22 0%	0 0%	352 6%
JUL-2022	24 69%	2745 47%	7 20%	2452 42%	3 9%	297 5%	0 0%	0 0%	0 0%	22 0%	1 3%	342 6%
AUG-2022	26 76%	2790 48%	6 18%	2452 42%	1 3%	294 5%	0 0%	0 0%	1 3%	22 0%	1 3%	340 6%
SEP-2022	19 76%	2820 48%	6 24%	2433 42%	0 0%	281 5%	0 0%	0 0%	0 0%	21 0%	0 0%	323 6%
OCT-2022	28 80%	2889 49%	6 17%	2440 41%	1 3%	280 5%	0 0%	0 0%	0 0%	22 0%	0 0%	314 5%
NOV-2022	24 73%	2920 49%	8 24%	2462 41%	1 3%	276 5%	0 0%	1 0%	0 0%	22 0%	0 0%	309 5%
DEC-2022	16 70%	2975 50%	5 22%	2466 41%	1 4%	270 4%	0 0%	1 0%	0 0%	20 0%	1 4%	308 5%
JAN-2023	23 82%	3018 50%	5 18%	2494 41%	0 0%	269 4%	0 0%	1 0%	0 0%	21 0%	0 0%	303 5%
FEB-2023	20 77%	3046 50%	6 23%	2480 41%	0 0%	255 4%	0 0%	1 0%	0 0%	21 0%	0 0%	288 5%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	654	8.73	76	1.01
AUG-2022	829	11.06	691	9.22	4610	61.52	641	8.55	648	8.65	74	0.99
SEP-2022	800	10.75	691	9.28	4575	61.47	662	8.89	641	8.61	74	0.99
OCT-2022	789	10.56	673	9.01	4620	61.86	678	9.08	636	8.52	73	0.98
NOV-2022	770	10.26	682	9.09	4639	61.84	694	9.25	645	8.60	72	0.96
DEC-2022	773	10.24	663	8.78	4684	62.06	706	9.35	650	8.61	71	0.94
JAN-2023	752	9.91	665	8.76	4733	62.37	718	9.46	648	8.54	72	0.95
FEB-2023	717	9.52	666	8.84	4722	62.68	733	9.73	625	8.30	71	0.94

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	14	2	2	4	1	5	279

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2022	12306	3762
FEB-2022	12329	3776
MAR-2022	12358	3792
APR-2022	12387	3817
MAY-2022	12378	3806
JUN-2022	12393	3808
JUL-2022	12419	3817
AUG-2022	12440	3829
SEP-2022	12459	3838
OCT-2022	12486	3859
NOV-2022	12493	3848
DEC-2022	12471	3831
JAN-2023	12464	3818
FEB-2023	12452	3801

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved


**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants Feb-2023 N = 7534

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Feb-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Feb-2023

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Feb-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Feb-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Feb-2023

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>45</b>	<b>61</b>	<b>27</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>75</b>	<b>103</b>	<b>53</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>428</b>	<b>584</b>	<b>317</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>223</b>	<b>302</b>	<b>169</b>	
<b>Total HA:</b>		<b>771</b>	<b>1050</b>	<b>566</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>771</b>	<b>1050</b>	<b>566</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	160	218	122
Male	611	832	444

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	566	56	660	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	25	13
	5 years or more	12	6
	<5 years	8	8
	<b>Total HSDA:</b>	<b>45</b>	<b>27</b>
KOOTENAY BOUNDARY	10 years or more	47	30
	5 years or more	14	11
	<5 years	14	12
	<b>Total HSDA:</b>	<b>75</b>	<b>53</b>
OKANAGAN	10 years or more	277	202
	5 years or more	82	60
	<5 years	69	55
	<b>Total HSDA:</b>	<b>428</b>	<b>317</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	141	110
	5 years or more	44	30
	<5 years	38	29
	<b>Total HSDA:</b>	<b>223</b>	<b>169</b>
<b>Total HA:</b>		<b>771</b>	<b>566</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	490	355
	5 years or more	152	107
	<5 years	129	104
<b>Total HA:</b>		<b>771</b>	<b>566</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	11	19
KOOTENAY BOUNDARY	78	137	23	47
OKANAGAN	239	1072	53	353
THOMPSON/CARIBOO/SHUSWAP	151	559	37	140
<b>Total:</b>	<b>519</b>	<b>1838</b>	<b>124</b>	<b>559</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	8
KOOTENAY BOUNDARY	11
OKANAGAN	58
THOMPSON/CARIBOO/SHUSWAP	43
<b>Total:</b>	<b>120</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	38	40	29
	35-49	101	105	65
	50+	258	359	190
	<b>Total HSDA:</b>	<b>404</b>	<b>511</b>	<b>291</b>
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>1141</b>	<b>1543</b>	<b>865</b>
FRASER SOUTH	0-19	9	9	9
	20-34	101	103	72
	35-49	297	324	231
	50+	624	949	510
	<b>Total HSDA:</b>	<b>1031</b>	<b>1385</b>	<b>822</b>
<b>Total HA:</b>		<b>2576</b>	<b>3439</b>	<b>1978</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	17
	20-34	266	271	184
	35-49	758	815	580
	50+	1535	2336	1197
<b>Total HA:</b>		<b>2576</b>	<b>3439</b>	<b>1978</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	626	799	468
Male	1950	2640	1510

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1978	53	650	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	264	191
	5 years or more	71	43
	<5 years	69	57
	<b>Total HSDA:</b>	<b>404</b>	<b>291</b>
FRASER NORTH	10 years or more	713	514
	5 years or more	237	188
	<5 years	191	163
	<b>Total HSDA:</b>	<b>1141</b>	<b>865</b>
FRASER SOUTH	10 years or more	645	498
	5 years or more	215	172
	<5 years	171	152
	<b>Total HSDA:</b>	<b>1031</b>	<b>822</b>
<b>Total HA:</b>		<b>2576</b>	<b>1978</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1622	1203
	5 years or more	523	403
	<5 years	431	372
<b>Total HA:</b>		<b>2576</b>	<b>1978</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	148	535	34	65
FRASER NORTH	260	1611	39	219
FRASER SOUTH	227	1785	49	486
<b>Total:</b>	<b>635</b>	<b>3931</b>	<b>122</b>	<b>770</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	202
FRASER NORTH	713
FRASER SOUTH	463
<b>Total:</b>	<b>1378</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>352</b>	<b>521</b>
RICHMOND	20-34	32	33	20
	35-49	52	53	42
	50+	117	172	94
	<b>Total HSDA:</b>	<b>201</b>	<b>258</b>	<b>156</b>
VANCOUVER	0-19	12	12	10
	20-34	444	458	302
	35-49	1233	1374	865
	50+	2974	5294	2122
	<b>Total HSDA:</b>	<b>4663</b>	<b>7138</b>	<b>3299</b>
<b>Total HA:</b>		<b>5216</b>	<b>7917</b>	<b>3728</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	11
	20-34	503	518	339
	35-49	1362	1512	961
	50+	3338	5874	2417
<b>Total HA:</b>		<b>5216</b>	<b>7917</b>	<b>3728</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	601	964	443
Male	4613	6951	3285
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3728	55	650	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	238	185
	5 years or more	54	44
	<5 years	60	44
	<b>Total HSDA:</b>	<b>352</b>	<b>273</b>
RICHMOND	10 years or more	122	91
	5 years or more	36	25
	<5 years	43	40
	<b>Total HSDA:</b>	<b>201</b>	<b>156</b>
VANCOUVER	10 years or more	*	2221
	5 years or more	*	605
	<5 years	*	473
	Never on ART	*	0
	<b>Total HSDA:</b>	<b>4663</b>	<b>3299</b>
<b>Total HA:</b>	<b>5216</b>	<b>3728</b>	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	*	2497
	5 years or more	*	674
	<5 years	*	557
	Never on ART	*	0
<b>Total HA:</b>		<b>5216</b>	<b>3728</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	187	417	40	60
RICHMOND	45	311	9	93
VANCOUVER	679	11520	212	5418
<b>Total:</b>	<b>911</b>	<b>12248</b>	<b>261</b>	<b>5571</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>75</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>361</b>	<b>522</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>126</b>	<b>177</b>
SOUTH VANCOUVER ISLAND	20-34	71	77	48
	35-49	191	217	145
	50+	538	858	407
	<b>Total HSDA:</b>	<b>800</b>	<b>1152</b>	<b>600</b>
<b>Total HA:</b>		<b>1287</b>	<b>1851</b>	<b>992</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>1287</b>	<b>1851</b>	<b>992</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	221	320	169
Male	1066	1531	823

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	992	56	590	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	218	178
	5 years or more	79	57
	<5 years	64	55
	<b>Total HSDA:</b>	<b>361</b>	<b>290</b>
NORTH VANCOUVER ISLAND	10 years or more	86	71
	5 years or more	26	19
	<5 years	14	12
	<b>Total HSDA:</b>	<b>126</b>	<b>102</b>
SOUTH VANCOUVER ISLAND	10 years or more	491	351
	5 years or more	161	128
	<5 years	148	121
	<b>Total HSDA:</b>	<b>800</b>	<b>600</b>
<b>Total HA:</b>		<b>1287</b>	<b>992</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	795	600
5 years or more	266	204
<5 years	226	188
<b>Total HA:</b>	<b>1287</b>	<b>992</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	203	923	73	163
NORTH VANCOUVER ISLAND	157	280	37	68
SOUTH VANCOUVER ISLAND	222	1934	34	587
<b>Total:</b>	<b>582</b>	<b>3137</b>	<b>144</b>	<b>818</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	116
NORTH VANCOUVER ISLAND	43
SOUTH VANCOUVER ISLAND	130
<b>Total:</b>	<b>289</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	5
	35-49	15	18	11
	50+	28	36	15
	<b>Total HSDA:</b>	<b>51</b>	<b>62</b>	<b>31</b>
NORTH WEST	20-34	*	6	*
	35-49	*	38	*
	50+	*	75	*
	<b>Total HSDA:</b>	<b>71</b>	<b>119</b>	<b>51</b>
NORTHERN INTERIOR	0-19	6	6	*
	20-34	19	19	*
	35-49	57	74	*
	50+	115	196	*
	<b>Total HSDA:</b>	<b>197</b>	<b>295</b>	<b>147</b>
<b>Total HA:</b>		<b>319</b>	<b>476</b>	<b>229</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	31	33	*
	35-49	96	130	*
	50+	186	307	*
<b>Total HA:</b>		<b>319</b>	<b>476</b>	<b>229</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	113	174	76
Male	206	302	153

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	229	53	605	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	30	*
	5 years or more	6	*
	<5 years	15	*
	<b>Total HSDA:</b>	<b>51</b>	<b>31</b>
NORTH WEST	10 years or more	51	35
	5 years or more	10	9
	<5 years	10	7
	<b>Total HSDA:</b>	<b>71</b>	<b>51</b>
NORTHERN INTERIOR	10 years or more	104	79
	5 years or more	60	41
	<5 years	33	27
	<b>Total HSDA:</b>	<b>197</b>	<b>147</b>
<b>Total HA:</b>		<b>319</b>	<b>229</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	185	129
	5 years or more	76	54
	<5 years	58	46
<b>Total HA:</b>		<b>319</b>	<b>229</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	40	60	6	8
NORTH WEST	85	173	15	36
NORTHERN INTERIOR	124	500	22	193
<b>Total:</b>	<b>249</b>	<b>733</b>	<b>43</b>	<b>237</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	5
NORTH WEST	19
NORTHERN INTERIOR	12
<b>Total:</b>	<b>36</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





### 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	12	5
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	32	52	21
	THOMPSON/CARIBOO/SHUSWAP	26	50	19
	<b>Total HA:</b>	<b>70</b>	<b>123</b>	<b>50</b>
FRASER	FRASER EAST	35	50	28
	FRASER NORTH	44	86	35
	FRASER SOUTH	82	118	62
	<b>Total HA:</b>	<b>161</b>	<b>254</b>	<b>125</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	51	21
	RICHMOND	6	11	5
	VANCOUVER	461	908	375
	<b>Total HA:</b>	<b>492</b>	<b>970</b>	<b>401</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	81	38
	NORTH VANCOUVER ISLAND	16	30	11
	SOUTH VANCOUVER ISLAND	49	96	40
	<b>Total HA:</b>	<b>112</b>	<b>207</b>	<b>89</b>
NORTHERN	NORTH EAST	9	13	5
	NORTH WEST	31	67	22
	NORTHERN INTERIOR	68	115	53
	<b>Total HA:</b>	<b>108</b>	<b>195</b>	<b>80</b>
<b>Total:</b>		<b>943</b>	<b>1749</b>	<b>745</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	599	1123	468
Female	344	626	277

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	745	53	530	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir:** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Antiretroviral:** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla:** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Complera:** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Descovy:** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay):** an INTEGRASE INHIBITOR from ViiV Healthcare.





## Monthly Report

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir:** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine:** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intelence):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fostemsavir:** an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa:** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine:** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.





## Monthly Report

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**N(t)RTI:** a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Odefsey:** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix:** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.





## Monthly Report

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Stavudine (Zerit):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq:** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir:** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada:** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

